Actinium Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Actinium Pharmaceuticals, Inc.
New Data Bolster Prospects For Actinium's Radioligand
The US firm has announced positive survival data from a Phase III trial of it radioligand therapy, Iomab-B, in acute myeloid leukemia patients prior to bone transplant, improving its cost-effectiveness case and commercial strategy.
Actinium Seeks to Disrupt As Radioligand Candidate Succeeds In Pivotal Pre-Transplant AML Trial
The US firm’s lead asset has impressed as a conditioning regimen for AML patients undergoing bone marrow transplant, boding well for an ongoing US filing as the firm works to disrupt the transplant space across a range of blood cancers.
Deal Watch: Dragonfly Adds Gilead To Its List Of Big-Name Partners
AbbVie inks collaboration and option deal focused on targeted protein degradation with Plexium. Cend and Calabrius merge in an all-stock transaction.
Deal Watch: AbbVie Adds Neuroscience Heft With Syndesi Acquisition
AbbVie pays $130m up front with up to $870m in earnout potential for UCB spinout focused on SV2A modulators. BioNTech gets rights to preclinical TCR candidates for solid tumors from Medigene.
- Radiopharmaceuticals, Contrast Agents
- Drug Discovery Tools
- Other Names / Subsidiaries
- Cactus Ventures, Inc. (CTVN)
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.